Literature DB >> 12161225

Technical feasibility, safety, and clinical outcome of stenting of unprotected left main coronary artery bifurcation narrowing.

Seung-Jung Park1, Cheol Whan Lee, Young-Hak Kim, Jae-Hwan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park.   

Abstract

This study was performed to evaluate the acute and long-term results of stenting for unprotected left main coronary artery (LMCA) bifurcation lesions. Sixty-three consecutive patients with an unprotected LMCA bifurcation lesion and normal left ventricular function were included. Stenting was performed with (n = 32) or without debulking atherectomy (n = 31) at the operator's discretion. Slotted-tube stents, coil stents, or bifurcation stents were used. The procedural success rate was 100%. In-hospital events including stent thrombosis, Q-wave myocardial infarction, and emergency bypass surgery did not occur in any patients. The angiographic follow-up rate was 86% (43 of the 50 eligible patients), and the restenosis rate was 28% (parent vessel only 14%, side branch only 9%, and both 5%). Restenosis at the parent vessel occurred less frequently in the debulking group than in the nondebulking group (5% vs 33%, respectively, p = 0.02). In multivariate analysis, the debulking procedure was an independent predictive factor of restenosis for the parent vessel (odds ratio 0.10, 95% confidence intervals 0.01 to 0.91, p = 0.04). Clinical follow-up was obtained in all patients at 19.9 +/- 13.7 months. There were 2 deaths (noncardiac origin), but no myocardial infarction during follow-up. Target lesion revascularization was required in 6 patients. The event-free survival rate (death, nonfatal myocardial infarction, and repeat revascularization) was 86% at the end of the follow-up period. In conclusion, stenting for an unprotected LMCA bifurcation lesion may be performed with a high procedural success rate and a favorable clinical outcome in selected patients with normal left ventricular function, suggesting that stenting would be an effective alternative to surgery in these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12161225     DOI: 10.1016/s0002-9149(02)02492-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Left main coronary artery compression in a young woman with Eisenmenger syndrome.

Authors:  Tobias Koppara; Julinda Mehilli; Alfred Hager; Harald Kaemmerer
Journal:  Heart Asia       Date:  2011-01-01

2.  Treatment of patients with left main coronary artery disease.

Authors:  Seung-Jung Park; Duk-Woo Park
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02

3.  Angioplasty of the left main coronary artery: Mid-term follow-up at University Medical Centre Groningen.

Authors:  W T Ruifrok; G A J Jessurun; R A Tio; F Zijlstra
Journal:  Neth Heart J       Date:  2005-10       Impact factor: 2.380

4.  Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry.

Authors:  Giuseppe G L Biondi-Zoccai; Elena Giraudi; Claudio Moretti; Filippo Sciuto; Pierluigi Omedè; Dario Sillano; Paolo Garrone; Gian Paolo Trevi; Imad Sheiban
Journal:  Clin Res Cardiol       Date:  2010-01-03       Impact factor: 5.460

5.  Stenting of unprotected left main stem stenosis: Results from a German single-centre registry.

Authors:  Klaus Hertting; Tobias Härle; Korff Krause; Jacobus Reimers; Sigrid Boczor; Karl-Heinz Kuck
Journal:  Exp Clin Cardiol       Date:  2008

Review 6.  Revascularization for unprotected left main coronary artery disease: an evolution in clinical decision making.

Authors:  David E Kandzari; John A Ormiston
Journal:  Curr Cardiol Rep       Date:  2011-10       Impact factor: 2.931

7.  Comparison of bypass surgery with drug-eluting stents in diabetic patients with left main coronary stenosis.

Authors:  Xiaoxiao Zhao; Yujie Zhou; Hui Song; Like Guan; Guanbin Zheng; Zhehu Jin; Dongmei Shi; Yuzi Li; Yonghe Guo; Guo-Ping Shi; Xian Wu Cheng
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.